{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:56:17Z","timestamp":1792079777302,"version":"4.4.0"},"reference-count":95,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>\n                    Rett syndrome (RTT) is a severe X-linked neurodevelopmental disorder affecting approximately 1 in 10,000\u201315,000 females, most often caused by loss-of-function mutations in\n                    <jats:italic>MECP2<\/jats:italic>\n                    . Until the recent approval of trofinetide, management relied exclusively on symptomatic treatment and multidisciplinary supportive care. The therapeutic landscape is now undergoing a rapid shift, driven by multiple gene therapy approaches designed to restore functional MeCP2 expression and achieve true disease modification. As these therapies progress toward potential regulatory approval, neurologists will play central roles in identifying eligible patients, counseling families, supporting clinical trial enrollment, delivering treatments, monitoring long-term outcomes, and advocating for equitable access. This review provides neurologists with the essential framework needed to understand and navigate this evolving field. We examine in detail the two most advanced gene replacement therapies currently in clinical trials. TSHA-102 uses an intrathecally delivered miniMECP2 transgene regulated by a microRNA-based autoregulatory system, whereas NGN-401 delivers full-length\n                    <jats:italic>MECP2<\/jats:italic>\n                    via intracerebroventricular administration using a synthetic expression-feedback circuit. Both approaches have shown encouraging early efficacy, with treated children achieving developmental gains that exceed natural history expectations. However, they differ substantially in molecular design, regulatory control, delivery method, and safety considerations. We also highlight challenges unique to RTT gene therapy, including the narrow therapeutic window between insufficient expression and MeCP2 overexpression toxicity, the impact of X-chromosome inactivation mosaicism, and lessons learned from a fatal hyperinflammatory adverse event. Beyond AAV-mediated gene replacement, we review next-generation strategies in preclinical development\u2014CRISPR-Cas9 genome editing for permanent mutation correction, ADAR-based RNA editing, translation readthrough for nonsense variants, and X-chromosome reactivation to restore endogenous\n                    <jats:italic>MECP2<\/jats:italic>\n                    expression. Finally, we address key translational considerations such as optimal timing of intervention, dosing constraints, outcome measurement in severely impaired populations, long-term safety surveillance, and barriers to broad and equitable access. The RTT gene therapy experience serves as a model for precision medicine in other monogenic neurodevelopmental disorders, illustrating both the transformative promise and the substantial complexities of translating genetic science into meaningful clinical benefit.\n                  <\/jats:p>","DOI":"10.3389\/fneur.2026.1766679","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T06:29:44Z","timestamp":1768890584000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Disease-modifying therapies for Rett syndrome: a review for neurologists"],"prefix":"10.3389","volume":"17","author":[{"given":"Debopam","family":"Samanta","sequence":"first","affiliation":[{"name":"Division of Child Neurology, Department of Pediatrics, University of Arkansas for Medical Sciences","place":["Little Rock, AR, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41431-019-0508-0","article-title":"Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database","volume":"28","author":"Nguengang Wakap","year":"2020","journal-title":"Eur J Hum Genet"},{"key":"ref2","year":"2025"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/ejhg.2017.64","article-title":"Practices and views of neurologists regarding the use of whole-genome sequencing in clinical settings: a web-based survey","volume":"25","author":"Jaitovich Groisman","year":"2017","journal-title":"Eur J Hum Genet"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/s10897-013-9624-0","article-title":"Use of genetic tests among neurologists and psychiatrists: knowledge, attitudes, behaviors, and needs for training","volume":"23","author":"Salm","year":"2014","journal-title":"J Genet Couns"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13643-023-02169-6","article-title":"Global prevalence of Rett syndrome: systematic review and Meta-analysis","volume":"12","author":"Petriti","year":"2023","journal-title":"Syst Rev"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1097\/01.mop.0000143693.59408.ce","article-title":"Rett syndrome: clinical and molecular update","volume":"16","author":"Percy","year":"2004","journal-title":"Curr Opin Pediatr"},{"key":"ref7","first-page":"723","article-title":"On a unusual brain atrophy syndrome in Hyperammonemia in childhood","volume":"116","author":"Rett","year":"1966","journal-title":"Wien Med Wochenschr"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1002\/ana.410140412","article-title":"A progressive syndrome of autism, dementia, Ataxia, and loss of purposeful hand use in girls: Rett's syndrome: report of 35 cases","volume":"14","author":"Hagberg","year":"1983","journal-title":"Ann Neurol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/13810","article-title":"Rett syndrome is caused by mutations in X-linked Mecp2, encoding methyl-Cpg-binding protein 2","volume":"23","author":"Amir","year":"1999","journal-title":"Nat Genet"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1002\/1096-8628(200022)97:2<147::aid-ajmg6>3.0.co;2-o","article-title":"Rett syndrome: methyl-Cpg-binding protein 2 mutations and phenotype-genotype correlations","volume":"97","author":"Amir","year":"2000","journal-title":"Am J Med Genet"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/s0387-7604(85)80048-6","article-title":"Rett syndrome: criteria for inclusion and exclusion","volume":"7","author":"Hagberg","year":"1985","journal-title":"Brain Dev"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/genes12081157","article-title":"Rett syndrome spectrum in monogenic developmental-epileptic encephalopathies and epilepsies: a review","volume":"12","author":"Spagnoli","year":"2021","journal-title":"Genes"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/ajmg.a.34367","article-title":"Medical care of adolescents and women with Rett syndrome: an Italian study","author":"Vignoli","year":"2012","journal-title":"Am J Med Genet A"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/1750-1172-9-87","article-title":"Twenty years of surveillance in Rett syndrome: what does this tell us?","volume":"9","author":"Anderson","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.yebeh.2007.10.010","article-title":"Clinical and electroencephalographic features in patients with Cdkl5 mutations: two new Italian cases and review of the literature","volume":"12","author":"Pintaudi","year":"2008","journal-title":"Epilepsy Behav"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1212\/WNL.0b013e3181d6b852","article-title":"Epilepsy and the natural history of Rett syndrome","volume":"74","author":"Glaze","year":"2010","journal-title":"Neurology"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1007\/s11011-018-0316-1","article-title":"Quality of life related to clinical features in patients with Rett syndrome and their parents: a systematic review","volume":"33","author":"Corch\u00f3n","year":"2018","journal-title":"Metab Brain Dis"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13023-023-02994-x","article-title":"Treatment guidelines for rare, early-onset conditions associated with epileptic seizures: a literature review on Rett syndrome and tuberous sclerosis complex","volume":"19","author":"Amin","year":"2024","journal-title":"Orphanet J Rare Dis"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1111\/jar.12694","article-title":"Non-medical interventions for individuals with Rett syndrome: a systematic review","volume":"33","author":"Amoako","year":"2020","journal-title":"J Appl Res Intellect Disabil"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1177\/0883073807308715","article-title":"Rett syndrome: north American database","volume":"22","author":"Percy","year":"2007","journal-title":"J Child Neurol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"e65393","DOI":"10.7759\/cureus.65393","article-title":"Insulin-like growth factor 1 has the potential to be used as a diagnostic tool and treatment target for autism spectrum disorders","volume":"16","author":"Shen","year":"2024","journal-title":"Cureus"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.tips.2023.06.008","article-title":"Trofinetide: a pioneering treatment for Rett syndrome","volume":"44","author":"Parent","year":"2023","journal-title":"Trends Pharmacol Sci"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"5023","DOI":"10.2147\/dddt.S383133","article-title":"Profile of trofinetide in the treatment of Rett syndrome: design, development and potential place in therapy","volume":"18","author":"Camillo","year":"2024","journal-title":"Drug Des Devel Ther"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"106704","DOI":"10.1016\/j.cct.2022.106704","article-title":"Design and outcome measures of Lavender, a phase 3 study of trofinetide for Rett syndrome","volume":"114","author":"Neul","year":"2022","journal-title":"Contemp Clin Trials"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1038\/s41591-023-02398-1","article-title":"Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study","volume":"29","author":"Neul","year":"2023","journal-title":"Nat Med"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.pediatrneurol.2023.11.005","article-title":"Trofinetide treatment demonstrates a benefit over placebo for the ability to communicate in Rett syndrome","volume":"152","author":"Neul","year":"2024","journal-title":"Pediatr Neurol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s12887-024-04526-3","article-title":"Safety and efficacy of trofinetide in Rett syndrome: a systematic review and meta-analysis of randomized controlled trials","volume":"24","author":"Abbas","year":"2024","journal-title":"BMC Pediatr"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"4767","DOI":"10.1007\/s10072-024-07584-8","article-title":"A meta-analysis of the efficacy and safety of trofinetide in patients with Rett syndrome","volume":"45","author":"Abo Zeid","year":"2024","journal-title":"Neurol Sci"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.medj.2025.100608","article-title":"Results from the phase 2\/3 Daffodil study of Trofinetide in girls aged 2-4 years with Rett syndrome","volume":"6","author":"Percy","year":"2025","journal-title":"Med"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/j.medj.2024.06.007","article-title":"Trofinetide for the treatment of Rett syndrome: long-term safety and efficacy results of the 32-month, open-label Lilac-2 study","volume":"5","author":"Percy","year":"2024","journal-title":"Med"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/j.medj.2024.05.018","article-title":"Trofinetide for the treatment of Rett syndrome: results from the open-label extension Lilac study","volume":"5","author":"Percy","year":"2024","journal-title":"Med"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"16482","DOI":"10.1111\/dmcn.16482","article-title":"Real-world benefits and tolerability of trofinetide for the treatment of Rett syndrome: the Lotus study","volume":"11","author":"Cosand","year":"2025","journal-title":"Dev Med Child Neurol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1126\/science.1138389","article-title":"Reversal of neurological defects in a mouse model of Rett syndrome","volume":"315","author":"Guy","year":"2007","journal-title":"Science"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"e12754","DOI":"10.1111\/gbb.12754","article-title":"Gene therapy for Rett syndrome","volume":"21","author":"Bassuk","year":"2022","journal-title":"Genes Brain Behav"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"109023","DOI":"10.3390\/ijms24109023","article-title":"Evidence synthesis of gene therapy and gene editing from different disorders-implications for individuals with Rett syndrome: a systematic review","volume":"24","author":"Singh","year":"2023","journal-title":"Int J Mol Sci"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1070904","DOI":"10.3390\/brainsci11070904","article-title":"The impact of X-chromosome inactivation on phenotypic expression of X-linked neurodevelopmental disorders","volume":"11","author":"Brand","year":"2021","journal-title":"Brain Sci"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1093\/hmg\/ddh142","article-title":"X-chromosome inactivation ratios affect wild-type Mecp2 expression within mosaic Rett syndrome and Mecp2\u2212\/+ mouse brain","volume":"13","author":"Braunschweig","year":"2004","journal-title":"Hum Mol Genet"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3389\/fpsyt.2012.00024","article-title":"X-chromosome inactivation in Rett syndrome human induced pluripotent stem cells","volume":"3","author":"Cheung","year":"2012","journal-title":"Front Psych"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"S182","DOI":"10.1016\/s0387-7604(01)00362-x","article-title":"The role of X-chromosome inactivation in the manifestation of Rett syndrome","author":"Takagi","year":"2001","journal-title":"Brain Dev"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1086\/382228","article-title":"X-chromosome inactivation patterns are unbalanced and affect the phenotypic outcome in a mouse model of Rett syndrome","volume":"74","author":"Young","year":"2004","journal-title":"Am J Hum Genet"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"e1989","DOI":"10.1002\/mgg3.1989","article-title":"Exploring the characteristics and most bothersome symptoms in Mecp2 duplication syndrome to pave the path toward developing parent-oriented outcome measures","volume":"10","author":"Ak","year":"2022","journal-title":"Mol Genet Genomic Med"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/j.1399-0004.1996.tb03285.x","article-title":"A comparative study of X-inactivation in Rett syndrome Probands and control subjects","volume":"49","author":"Webb","year":"1996","journal-title":"Clin Genet"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"e6810","DOI":"10.1371\/journal.pone.0006810","article-title":"Mecp2 isoform-specific vectors with regulated expression for Rett syndrome gene therapy","volume":"4","author":"Rastegar","year":"2009","journal-title":"PLoS One"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/mt.2012.200","article-title":"Improved survival and reduced phenotypic severity following Aav9\/Mecp2 gene transfer to neonatal and juvenile male Mecp2 knockout mice","volume":"21","author":"Gadalla","year":"2013","journal-title":"Mol Ther"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.omtm.2017.04.007","article-title":"Development of a novel Aav gene therapy cassette with improved safety features and efficacy in a mouse model of Rett syndrome","volume":"5","author":"Gadalla","year":"2017","journal-title":"Mol Ther Methods Clin Dev"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"13612","DOI":"10.1523\/jneurosci.1854-13.2013","article-title":"Systemic delivery of Mecp2 rescues behavioral and cellular deficits in female mouse models of Rett syndrome","volume":"33","author":"Garg","year":"2013","journal-title":"J Neurosci"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nbd.2016.12.009","article-title":"A codon-optimized Mecp2 transgene corrects breathing deficits and improves survival in a mouse model of Rett syndrome","volume":"99","author":"Matagne","year":"2017","journal-title":"Neurobiol Dis"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"105235","DOI":"10.1016\/j.nbd.2020.105235","article-title":"Severe offtarget effects following intravenous delivery of Aav9-Mecp2 in a female mouse model of Rett syndrome","volume":"149","author":"Matagne","year":"2021","journal-title":"Neurobiol Dis"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s12264-022-00974-y","article-title":"Extension of the lifespan of a mouse model of Rett syndrome by intracerebroventricular delivery of Mecp2","volume":"39","author":"Yang","year":"2023","journal-title":"Neurosci Bull"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.52629","article-title":"Whole brain delivery of an instability-prone Mecp2 transgene improves behavioral and molecular pathological defects in mouse models of Rett syndrome","volume":"9","author":"Luoni","year":"2020","journal-title":"eLife"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3233\/trd-230063","article-title":"Irsf 2023 - Rett syndrome scientific meeting report","volume":"6","author":"Garg","year":"2023","journal-title":"Transl Sci Rare Dis"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/nature24058","article-title":"Radically truncated Mecp2 rescues Rett syndrome-like neurological defects","volume":"550","author":"Tillotson","year":"2017","journal-title":"Nature"},{"key":"ref53","article-title":"The efficacy of a human-ready mini MECP2 gene therapy in a pre-clinical model of Rett syndrome","author":"Sadhu","year":"2023"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1093\/brain\/awab182","article-title":"Engineered Microrna-based regulatory element permits safe high-dose Minimecp2 gene therapy in Rett mice","volume":"144","author":"Sinnett","year":"2021","journal-title":"Brain"},{"key":"ref55","article-title":"Raav9 vector biodistribution in brain and spinal cord via lumbar intrathecal infusion in nonhuman Primates (Nhp): assessing the administration route leveraged in Tsha-102 Rett syndrome clinical trials","author":"Emdadul Haque","year":"2025"},{"key":"ref56","volume-title":"Promising phase 1\/2 data released on Rett syndrome gene therapy agent Tsha-102NeurologyLive","author":"Meglio","year":"2023"},{"key":"ref57","article-title":"Second patient dosing recommended for Tsha-102 gene therapy trial in Rett syndrome","volume-title":"NeurologyLive","author":"Stansfield","year":"2023"},{"key":"ref58","article-title":"First-cohort data from the Reveal adolescent\/adult and pediatric studies of Tsha-102 gene therapy for Rett syndrome","author":"Nagendran","year":"2025"},{"key":"ref59","article-title":"Every gain, expanding possibilities: caregiver insights on meaningful improvement in Rett syndrome gene therapy","author":"Keeley","year":"2025"},{"key":"ref60","article-title":"Achieving developmental milestones and broad restoration of function in Rett syndrome: the potential of Tsha-102 gene therapy","author":"Elsa Rossignol","year":"2025"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"eadq3614","DOI":"10.1126\/scitranslmed.adq3614","article-title":"Self-regulating gene therapy ameliorates phenotypes and overcomes gene dosage sensitivity in a mouse model of Rett syndrome","volume":"17","author":"Ross","year":"2025","journal-title":"Sci Transl Med"},{"key":"ref62","article-title":"Intracerebroventricular (Icv) delivery of Ngn-401 drives superior transgene expression to Key areas of the brain when compared to lumbar intrathecal (it-L) delivery at a clinically relevant dose \u2013 implications for a one-time gene therapy for Rett syndrome","author":"Burstein","year":"2025"},{"key":"ref63","article-title":"Ngn-401, a novel regulated gene therapy for Rett syndrome: preliminary results from the first-in-human study","author":"Suter","year":"2024"},{"key":"ref64","article-title":"Hemophagocytic Lymphohistiocytosis (Hlh)\/Hyperinflammatory syndrome following high dose Aav9 therapy","author":"Donald","year":"2025"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1146\/annurev-biophys-062215-010822","article-title":"Crispr\u2013Cas9 structures and mechanisms","volume":"46","author":"Jiang","year":"2017","journal-title":"Annu Rev Biophys"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.cell.2013.08.021","article-title":"Double nicking by Rna-guided Crispr Cas9 for enhanced genome editing specificity","volume":"154","author":"Ran","year":"2013","journal-title":"Cell"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"625","DOI":"10.3389\/fgene.2019.00625","article-title":"Efficient and precise Crispr\/Cas9-mediated Mecp2 modifications in human-induced pluripotent stem cells","volume":"10","author":"Le","year":"2019","journal-title":"Front Genet"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1089\/crispr.2022.0020","article-title":"Gene editing and Rett syndrome: does it make the cut?","volume":"5","author":"Coorey","year":"2022","journal-title":"CRISPR J"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"E9395","DOI":"10.1073\/pnas.1715320114","article-title":"Site-directed Rna repair of endogenous Mecp2 Rna in neurons","volume":"114","author":"Sinnamon","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"e2206053119","DOI":"10.1073\/pnas.2206053119","article-title":"Targeted Rna editing in brainstem alleviates respiratory dysfunction in a mouse model of Rett syndrome","volume":"119","author":"Sinnamon","year":"2022","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s00109-024-02436-6","article-title":"Systematic and quantitative analysis of stop codon readthrough in Rett syndrome nonsense mutations","volume":"102","author":"Lebeda","year":"2024","journal-title":"J Mol Med"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s00109-010-0704-4","article-title":"Readthrough of nonsense mutations in Rett syndrome: evaluation of novel aminoglycosides and generation of a new mouse model","volume":"89","author":"Brendel","year":"2011","journal-title":"J Mol Med"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1093\/hmg\/ddaa102","article-title":"Pharmacological read-through of R294x Mecp2 in a novel mouse model of Rett syndrome","volume":"29","author":"Merritt","year":"2020","journal-title":"Hum Mol Genet"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.tig.2022.01.007","article-title":"Selective xi reactivation and alternative methods to restore Mecp2 function in Rett syndrome","volume":"38","author":"Grimm","year":"2022","journal-title":"Trends Genet"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"E668","DOI":"10.1073\/pnas.1715124115","article-title":"A mixed modality approach towards xi reactivation for Rett syndrome and other X-linked disorders","volume":"115","author":"Carrette","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"8185","DOI":"10.1073\/pnas.1800931115","article-title":"Tsix-Mecp2 female mouse model for Rett syndrome reveals that low-level Mecp2 expression extends life and improves neuromotor function","volume":"115","author":"Carrette","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"12591","DOI":"10.1073\/pnas.1413620111","article-title":"Genetic and pharmacological reactivation of the mammalian inactive X chromosome","volume":"111","author":"Bhatnagar","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"7991","DOI":"10.1073\/pnas.1803792115","article-title":"Pharmacological reactivation of inactive X-linked Mecp2 in cerebral cortical neurons of living mice","volume":"115","author":"Przanowski","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1073\/pnas.1621356114","article-title":"Screen for reactivation of Mecp2 on the inactive X chromosome identifies the bmp\/Tgf-\u0392 superfamily as a regulator of Xist expression","volume":"114","author":"Sripathy","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s11689-020-09332-3","article-title":"A small-molecule screen reveals novel modulators of Mecp2 and X-chromosome inactivation maintenance","volume":"12","author":"Lee","year":"2020","journal-title":"J Neurodev Disord"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"6169","DOI":"10.1038\/s41467-025-61092-7","article-title":"Targeting microrna-dependent control of X chromosome inactivation improves the Rett syndrome phenotype","volume":"16","author":"Lou","year":"2025","journal-title":"Nat Commun"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"eadd4666","DOI":"10.1126\/scitranslmed.add4666","article-title":"Multiplex epigenome editing of Mecp2 to rescue Rett syndrome neurons","volume":"15","author":"Qian","year":"2023","journal-title":"Sci Transl Med"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1038\/nature14444","article-title":"Wild-type microglia do not reverse pathology in mouse models of Rett syndrome","volume":"521","author":"Wang","year":"2015","journal-title":"Nature"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"885335","DOI":"10.3389\/fnins.2022.885335","article-title":"Comprehensive volumetric analysis of Mecp2-null mouse model for Rett syndrome by T2-weighted 3d magnetic resonance imaging","volume":"16","author":"Akaba","year":"2022","journal-title":"Front Neurosci"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"4833","DOI":"10.7554\/eLife.64833","article-title":"Deleting Mecp2 from the cerebellum rather than its neuronal subtypes causes a delay in motor learning in mice","volume":"10","author":"Achilly","year":"2021","journal-title":"eLife"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"601626","DOI":"10.3389\/fphar.2021.601626","article-title":"Biodegradable polymeric nanoparticles for drug delivery to solid tumors","volume":"12","author":"Gagliardi","year":"2021","journal-title":"Front Pharmacol"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"1901081","DOI":"10.1002\/adma.201901081","article-title":"Cancer-targeting nanoparticles for combinatorial nucleic acid delivery","volume":"32","author":"Vaughan","year":"2020","journal-title":"Adv Mater"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"e0218623","DOI":"10.1371\/journal.pone.0218623","article-title":"Brain-enriched micrornas circulating in plasma as novel biomarkers for Rett syndrome","volume":"14","author":"Sheinerman","year":"2019","journal-title":"PLoS One"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3389\/fnint.2020.00030","article-title":"Evoked potentials and EEG analysis in Rett syndrome and related developmental encephalopathies: towards a biomarker for translational research","volume":"14","author":"Saby","year":"2020","journal-title":"Front Integr Neurosci"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1002\/ana.26948","article-title":"Electroencephalographic correlates of clinical severity in the natural history study of Rtt and related disorders","volume":"96","author":"Saby","year":"2024","journal-title":"Ann Neurol"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s11689-023-09479-9","article-title":"Comparison of evoked potentials across four related developmental encephalopathies","volume":"15","author":"Saby","year":"2023","journal-title":"J Neurodev Disord"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"1574758","DOI":"10.3389\/fnint.2025.1574758","article-title":"Considerations and procedures for acquiring EEG as part of multi-site studies for Rett syndrome and other genetic neurodevelopmental disorders","volume":"19","author":"Saby","year":"2025","journal-title":"Front Integr Neurosci"},{"key":"ref93","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/ana.26029","article-title":"Multisite study of evoked potentials in Rett syndrome","volume":"89","author":"Saby","year":"2021","journal-title":"Ann Neurol"},{"key":"ref94","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/s41398-020-00877-4","article-title":"Atypical processing of tones and phonemes in Rett syndrome as biomarkers of disease progression","volume":"10","author":"Sysoeva","year":"2020","journal-title":"Transl Psychiatry"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"1172805","DOI":"10.3389\/fnins.2023.1172805","article-title":"Advanced genetic therapies for the treatment of Rett syndrome: state of the art and future perspectives","volume":"17","author":"Palmieri","year":"2023","journal-title":"Front Neurosci"}],"updated-by":[{"DOI":"10.3389\/fneur.2026.1828621","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000}}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1766679\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T16:06:05Z","timestamp":1776701165000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1766679\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":95,"alternative-id":["10.3389\/fneur.2026.1766679"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2026.1766679","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,20]]},"article-number":"1766679"}}